A phase 2 randomized trial published in Nature Communications led by Wang, Ko and Leung evaluated GLP‑1 receptor agonists in patients with large‑vessel occlusion (LVO) stroke undergoing reperfusion. The study reported improved functional outcomes and biomarker signals linked to neuroprotection. Investigators randomized LVO patients receiving thrombectomy to adjunctive GLP‑1R therapy versus standard care and observed signal consistency across imaging and clinical endpoints. Authors propose GLP‑1 agonists’ pleiotropic effects—metabolic, anti‑inflammatory, and neurotrophic—may underlie benefit. The result positions GLP‑1 biology beyond metabolic disease into acute neuroprotection and could prompt larger confirmatory trials. Stroke neurologists and pharma will weigh timing, dosing, and safety in reperfusion settings.